Menu
Back to Journals » Infection and Drug Resistance » Volume 10
National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China
Authors Xiao M, Cheng JW, Kudinha T , Kong F, Xu YC
Received 16 August 2017
Accepted for publication 22 September 2017
Published 13 October 2017 Volume 2017:10 Pages 329—331
DOI https://doi.org/10.2147/IDR.S149293
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Joachim Wink
Meng Xiao,1,* Jing-Wei Cheng,1,2,* Timothy Kudinha,3 Fanrong Kong,4 Ying-Chun Xu1,2
1Department of Clinical Laboratory, Peking Union Medical College Hospital, 2Faculty of Clinical Laboratory Diagnostics, Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; 3School of Biomedical Sciences, The Charles Sturt University, Leeds Parade, Orange, 4Centre for Infectious Diseases and Microbiology Laboratory Services, ICPMR–Pathology West, Westmead Hospital, University of Sydney, Westmead, NSW, Australia
*These authors contributed equally to this work
In a recent report, Dingle et al showed that national intervention programs aimed at judicious antimicrobial usage, especially restrictions to fluoroquinolones, contributed to a significant decrease in Clostridium difficile infection (CDI) in England.1 This is considered an outstanding achievement in combating antimicrobial resistance worldwide.
Acknowledgments
This work was supported by a Natural Science Foundation of China (81501807), a Beijing Out-standing Talents Cultivation Program (2015000020124G071), and a PUMCH Youth Research Fund (grant number IH11583).
Author contributions
All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
Dingle KE, Didelot X, Quan TP, et al. Effects of control interventions on Clostridium difficile infection in England: an observational study. Lancet Infect Dis. 2017;17(4):411–421. | ||
China National Health and Family Planning Commission. The Administrative on the Clinical Use of Antimicrobial Agents and the Status Quo of Antimicrobial Resistance in China. Beijing, China: Pecking Union Medical College Press; 2016. | ||
Cheng JW, Xiao M, Kudinha T, et al. The first two Clostridium difficile ribotype 027/ST1 isolates identified in Beijing, China – an emerging problem or a neglected threat? Sci Rep. 2016;6:18834. | ||
Wang P, Zhou Y, Wang Z, et al. Identification of Clostridium difficile ribotype 027 for the first time in Mainland China. Infect Control Hosp Epidemiol. 2014;35(1):95–98. | ||
Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834. | ||
Xiao Y, Zhang J, Zheng B, Zhao L, Li S, Li L. Changes in Chinese policies to promote the rational use of antibiotics. PLoS Med. 2013;10(11): e1001556. | ||
Xiao Y, Li L. China’s national plan to combat antimicrobial resistance. Lancet Infect Dis. 2016;16(11):1216–1218. | ||
Quan J, Li X, Chen Y, et al. Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study. Lancet Infect Dis. 2017;17(4):400–410. | ||
Donskey CJ. Fluoroquinolone restriction to control fluoroquinolone-resistant Clostridium difficile. Lancet Infect Dis. 2017;17(4):353–354. |
© 2017 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.